JL 13, an atypical antipsychotic: A preclinical review

CNS Drug Reviews

Volumn 9, Issue 1, 2003, Pages 41-56

  Ellenbroek, Bart A ^a,c   Liégeois, Jean François ^b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Dept of Psychoneuropharmacology ^*  (Netherlands)

Author keywords

Agranulocytosis; Atypical antipsychotic; Clozapine; Extrapyramidal side effects; Haloperidol; Serotonin dopamine antagonist; Tricyclic

Indexed keywords

5 (4 METHYLPIPERAZIN 1YL) 8 CHLOROPYRIDO[2,3][1,5]BENZOXAZEPINE FUMARATE; APOMORPHINE; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; JL 13; LOXAPINE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; PEROXIDASE; PROLACTIN; RITANSERIN; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN DOPAMINE ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTONOMIC DYSFUNCTION; BLOOD BRAIN BARRIER; BLOOD TOXICITY; CATALEPSY; CHEMICAL MODIFICATION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOG; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DISCRIMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSTONIA; ELECTROOXIDATION POTENTIAL; ELECTROPHYSIOLOGY; EXTRACELLULAR SPACE; EXTRAPYRAMIDAL SYMPTOM; HEMATOLOGIC DISEASE; HYPERACTIVITY; HYPERPROLACTINEMIA; HYPERSALIVATION; LEARNING; MICRODIALYSIS; MOUSE; NEOSTRIATUM; NONHUMAN; NUCLEUS ACCUMBENS; OXIDATION REDUCTION POTENTIAL; PARKINSONISM; PHYSICAL CHEMISTRY; PREFRONTAL CORTEX; PREPULSE INHIBITION; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; PSYCHOSIS; PTOSIS; RAT; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SQUIRREL MONKEY; STEREOTYPY; TOXICOLOGY; TRANQUILIZING ACTIVITY;

EID: 0037361223     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2003.tb00243.x     Document Type: Review

References (92)

1. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: A situation report up to August 1976. Eur J Clin Pharmacol 1977;11:199-201.
2. Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ. Pharmacological profile of ritanserin: A specific central serotonin S2-antagonist. Drug Dev Res 1988;15:61-73.
3. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993;9:117-124.
4. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001;62(Suppl 23):45-66.
5. Bruhwyler J, Chleide E. Comparative study of the behavioral, neurophysiological, and motor effects of psychotropic drugs in the dog. Biol Psychiatry 1990;27:1264-1278.
6. Bruhwyler J, Chleide E, Houbeau G, Mercier M. Stimulant effect of the β-carboline FG 7142 in the openfield test. Eur J Pharmacol 1991;200:183-185.
7. Bruhwyler J, Chleide E, Houbeau G, Waegeneer N, Mercier M. Differentiation of haloperidol and clozapine using a complex operant schedule in the dog. Pharmacol Biochem Behav 1993;44:181-189.
8. Bruhwyler J, Chleide E, Liégeois J-F, Delarge J, Mercier M. Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test. Pharmacol Biochem Behav 1990;36:57-61.
9. Bruhwyler J, Liégeois J-F, Bergman J, et al. JL 13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioral properties. Pharmacol Res 1997;36:255-264.
10. Bruhwyler J, Liégeois J-F, Chleide E. et al. Comparative study of typical neuroleptics, clozapine and new synthesized clozapine-analogues: Correlations between neurochemistry and behaviour. Behav Pharmacol 1992;3:567-579.
11. Bruhwyler J, Liégeois J-F, Lejeune C, Rogister F, Delarge J, Géczy J. New dibenzazepine derivatives with disinhibitory and/or antidepressant potential: Neurochemical and behavioural study in the open-field and forced swimming tests. Behav Pharmacol 1995;6:830-838.
12. Carey GJ, Bergman J. Discriminative-stimulus effects of clozapine in squirrel monkeys: Comparison with conventional and novel antipsychotic drugs. Psychopharmacology 1997;132:261-269.
13. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 2001;41:237-260.
14. Casey DE. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys. Psychopharmacology 1996;124:134-140.
15. Cools AR, Prinssen EPM, Ellenbroek BA The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: Effect of risperidone, prothipendyl, ORG5222, sertindole and olanzapine. Psychopharmacology 1995;119:428-439.
16. Darmani NA, Martin BR, Glennon RA. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DO1) or ketanserin. J Pharmacol Exp Ther 1992;262:692-698.
17. 1C-mediated phenomenon. Pharmacol Biochem Behav 1994;48:383-396.
18. Davis KL, Kahn RS, Grant K, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991;148:1474-1486.
19. De Vry J, Benz U, Schreiber R, Traber J. Shock-induced ultrasonic vocalization in young adult rats: A model for testing putative anti-anxiety drugs. Eur J Pharmacol 1993;249:331-339.
20. Ellenbroek BA, Cools AR. The Paw test: An animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci 1988;42:1205-1213.
21. Ellenbroek BA, Liégeois J-F, Bruhwyler J, Cools AR. The effects of JL 13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J Pharmacol Exp Ther 2001;298:386-391.
22. Ellenbroek BA, Lubbers LJ, Cools AR Activity of seroquel (ICI 204,636) in animal models for atypical properties of antipsychotics - a comparison with clozapine. Neuropsychopharmacology 1996;15:406-416.
23. Ellenbroek BA, Peeters BW, Honig WM, Cools AR. The paw test: A behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 1987;93:343-348.
24. Ellenbroek BA, Prinssen EPM, Cools AR. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 1994;6:1-8.
25. Fischer V, Haar JA, Greiner L, Lloyd RV, Mason RP. Possible role of free radical formation in clozapine (Clozaril®)-induced agranulocytosis. Mol Pharmacol 1991;40:846-853.
26. 4.4 receptor. Br J Pharmacol 1998;124:889-896.
27. 2A receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 1999;38:315-317.
28. Goudie A, Taylor A. Comparative characterization of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology 1998;135:392-400.
29. Gross H, Langner E. Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe. Wien Med Wochenschr 1966;116:814-816.
30. Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori T, Meltzer HY. Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. J Neural Transm 1987;68:227-240.
31. Guiso G, Caccia S. Distribution of the methylpiperazinopyridobenzoxazepine derivative JL 13, a potential antipsychotic, in rat brain. J Pharm Pharmacol 2001;53:317-321.
32. 2-adrenoceptor blockade. Science 1999;286:105-107.
33. Hippius H. The history of clozapine. Psychopharmacology 1989;99:S3-S5.
34. 1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:1521-1531.
35. Invemizzi R, Garavaglia C, Samanin R. JL 13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats. Naunyn-Schmiedeberg's Arch Pharmacol 2000;361:298-302.
36. Ito C, Onodera K, Sakurai E, Sato M, Watanabe T. Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. J Pharmacol Exp Ther 1996;279:271-276.
37. 4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology 1999;142:78-84.
38. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: A doubleblind comparison with chlorpromazine. Arch Gen Psychiat 1988;45:789-796.
39. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 1997;54:567-572.
40. Kuroki T, Meltzer HY, Ichikawa J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999;284:774-781.
41. Liégeois J-F, Bruhwyler J, Damas J, et al. New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study. J Med Chem 1993;36:2107-2114.
42. 4 receptors. Eur J Pharmacol 1995;273:R1-R3.
43. Liégeois J-F, Bruhwyler J, Hendrick J-C, Delarge J, Legros J-J, Damas J. Minimal effects of JL 13, a pyridobenzoxazepine derivative with antipsychotic potential, on circulating prolactin levels in male rats. Neurosci Lett 2002;319:49-52.
44. Liégeois J-F, Bruhwyler J, Petit C, et al. Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: Application to antipsychotic drugs. Arch Biochem Biophys 1999;370:126-137.
45. A receptor blockers. Soc Neurosci Abstr 1997;23:949.
46. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 2002;947:157-165.
47. Liégeois J-F, Mouithys-Mickalad A, Bruhwyler J, et al. JL 13, a potential successor to clozapine is less sensitive to oxidative phenomenons. Biochem Biophys Res Commun 1997;238:252-255.
48. Liégeois J-F, Rogister F, Bruhwyler J, et al. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study. J Med Chem 1994;37:519-531.
49. Liégeois J-F, Rogister F, Delarge J, Pincemail J. Peroxidase-catalysed oxidation of different dibenzazepine derivatives. Arch Pharm 1995;328:109-112.
50. Liégeois J-F, Zahid N, Bruhwyler J, Uetrecht J. Hypochlorous acid, a major oxidant produced by activated neutrophils, has low effect on two pyridobenzoazepine derivatives, JL 3 and JL 13. Arch Pharm 2000;333:63-67.
51. Ljungberg T, Ungerstedt U. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action. Psychopharmacology 1978;56:239-247.
52. 4 receptor. Mol Brain Res 1995;29:157-162.
53. Meert TF. A comparative study of the effects of ritanserin (R55667) and chlordiazepoxide on rat open field behavior. Drug Dev Res 1986;8:197-204.
54. i values. J Pharmacol Exp Ther 1989;251:238-246.
55. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: An in vivo microdialysis study. J Neurochem 1990;54:1755-1760.
56. Moore NA, Rees G, Sanger G, Tye NC. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994;5:196-202.
57. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz J-C. Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther 1999;288:590-596.
58. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci. 1995;15:2186-2191.
59. Ögren SO, Hall H, Köhler C, et al. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 1984;102:459-474.
60. Peacock L, Gerlach J. New and old antipsychotics versus clozapine in a monkey model: Adverse effects and antiamphetamine effects. Psychopharmacology 1999;144:189-197.
61. Pehek EA, Yamamoto BK. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 1994;63:2118-2124.
62. Philpott NJ, Marsh JCW, Gordon-Smith EC, et al. Aplastic anaemia and remoxipride. Lancet 1993;342:1244-1245.
63. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn 1977;229:327-336.
64. Prinssen EPM, Ellenbroek BA, Cools AR. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 1994;262:167-170.
65. Prinssen EPM, Ellenbroek BA, Cools, AR. Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test. Br J Pharmacol 1994;112:769-774.
66. 2 receptors in the paw test, an animal model for the therapeutic efficacy and extrapyramidal side effects of neuroleptic drugs. Brain Res 1995;673:283-289.
67. 4 receptors increased in schizophrenia. J Neurochem 1994;63:1576-1577.
68. 4 receptors in drug-treated schizophrenia. Eur J Pharmacol 1995;281:R5-R6.
69. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 2000;68:29-39.
70. 1A receptor activation contributes to ziprasidoneinduced dopamine release in rat prefrontal cortex. Biol Psychiatry 2000;48:229-237.
71. 1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991;251:947-950.
72. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
73. Schwartz J-C, Arrang JM, Garbarg M, Pollard H, Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev 1991;71:1-51.
74. 4 receptors elevated in schizophrenia. Nature 1993;365:441-445.
75. 2 agonist, on substantia nigra and VTA dopaminergic neurons by JL 13, clozapine, and haloperidol. Int Neuropsychopharmacol 2000;3:S128.
76. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D-3) as a target for neuroleptics. Nature 1990;347:146-151.
77. 35S]-TBPS binding. Brain Res 1987;414:357-364.
78. Squires RF, Saederup E. A review for GABAergic predominance/glutamataergic deficit as a common etiological factor in both schizophrenia and affective psychoses: More support for a continuum hypothesis of "functional" psychosis. Neurochem Res 1991;16:1099-1111.
79. A receptors. Neurochem Res 1998;23:1283-1290.
80. Stille G, Hippius H. Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmakopsychiat 1971;4:182-191.
81. 2 dopamine receptor interaction at the biochemical level. Trends Pharmacol Sci 1991;12:48-49.
82. 2 antagonists endowed with anxiolytic properties in rodents? Neurosci Lett 1991;128:4-8.
83. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:149-154.
84. Swerdlow NR, Keith VA, Braff DL, Geyer MA. The effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine-inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 1991;256:530-536.
85. Swerdlow NR, Zisook D, Taaid N. Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine. Psychopharmacology 1994;114:675-678.
86. 2C serotonin receptors. Nature 1996;374:542-546.
87. 2A, antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry 1999;156:419-425.
88. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-135.
89. Uetrecht J, Zahid N, Tehim A, Mimfu J, Rakhit S. Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 1997;104:117-129.
90. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
91. Wiley JL, Compton AD, Porter JH. Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 1993;45:263-267.
92. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363.